Post Autologous Transplantation Consolidation of Multiple Myeloma with Idiotype-Pulsed Antigen Presenting (Dendritic) Cells (APC8020) Is Associated with Prolonged Survival.

@article{Lacy2008PostAT,
  title={Post Autologous Transplantation Consolidation of Multiple Myeloma with Idiotype-Pulsed Antigen Presenting (Dendritic) Cells (APC8020) Is Associated with Prolonged Survival.},
  author={Martha Q. Lacy and Sumithra J. Mandrekar and Brian F. Kabat and Angela Dispenzieri and Suzanne R. Hayman and Shaji K. Kumar and Francis K. Buadi and David Dingli and Mark R. Litzow and Peter J. Wettstein and Sundararajan Vincent Rajkumar and Dennis A Gastineau and Morie A. Gertz},
  journal={Blood},
  year={2008},
  volume={112},
  pages={1739-1739}
}
Introduction: Immunotherapy is most likely to work in a setting of low tumor burden, making vaccine strategies attractive as maintenance therapy post autologous peripheral blood stem cell transplantation (PBSCT) for multiple myeloma (MM). However, it is difficult to ascertain the effects of the vaccines from delayed responses to the transplant. A novel immunotherapeutic, APC8020 (Mylovenge), was studied as consolidation therapy after for MM post PBSCT (Mayo vaccine trial). Mylovenge is prepared…